[1]
|
Locke, F.L., Go, W.Y. and Neelapu, S.S. (2020) Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review. JAMA Oncology, 6, 281-290. https://doi.org/10.1001/jamaoncol.2019.3869
|
[2]
|
Benmebarek, M., Karches, C.H., Cadilha, B.L., et al. (2019) Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. International Journal of Molecular Sciences, 20, Article 1083. https://doi.org/10.3390/ijms20061283
|
[3]
|
Feins, S., Kong, W. and Williams, E.F., et al. (2019) An Introduction to Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy for Human Cancer. American Journal of Hematology, 94, S3-S9. https://doi.org/10.1002/ajh.25418
|
[4]
|
Uribe-Herranz, M., Klein-González, N., Rodríguez-Lobato, L.G., et al. (2021) Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure. International Journal of Molecular Sciences, 22, Article 1026. https://doi.org/10.3390/ijms22031026
|
[5]
|
Grigor, E., Fergusson, D. and Kekre, N., et al. (2019) Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. Transfusion Medicine Reviews, 33, 98-110. https://doi.org/10.1016/j.tmrv.2019.01.005
|
[6]
|
Ramakrishna, S., Barsan, V. and Mackall, C. (2020) Prospects and Challenges for Use of CAR T Cell Therapies in Solid Tumors. Expert Opinion on Biological Therapy, 20, 503-516. https://doi.org/10.1080/14712598.2020.1738378
|
[7]
|
Xu, D., Jin, G., Chai, D., et al. (2015) The Development of CAR Design for Tumor CAR-T Cell Therapy. Oncotarget, 9, 13991-14004. https://doi.org/10.18632/oncotarget.24179
|
[8]
|
Gross, G., Waks, T. and Eshhar, Z. (1989) Expression of Immunoglobulin-T-Cell Receptor Chimeric Molecules as Functional Receptors with Antibody-Type Specificity. Proceedings of the National Academy of Sciences of the United States of America, 86, 10024-10028. https://doi.org/10.1073/pnas.86.24.10024
|
[9]
|
Kuwana, Y., Asakura, Y., Utsunomiya, N., et al. (1987) Expression of Chimeric Receptor Composed of Immunoglobulin-Derived V Regions and T-Cell Receptor-Derived C Regions. Biochemical and Biophysical Research Communications, 149, 960-968. https://doi.org/10.1016/0006-291X(87)90502-X
|
[10]
|
Kershaw, M., Westwood, J., Parker, L., et al. (2006) A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 12, 6106-6115. https://doi.org/10.1158/1078-0432.CCR-06-1183
|
[11]
|
Brentjens, R., Rivière, I., Park, J., et al. (2011) Safety and Persistence of Adoptively Transferred Autologous CD19-Targeted T Cells in Patients with Relapsed or Chemotherapy Refractory B-Cell Leukemias. Blood, 118, 4817-4828. https://doi.org/10.1182/blood-2011-04-348540
|
[12]
|
Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A. and June, C.H. (2011) T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Science Translational Medicine, 3, 95ra73. https://doi.org/10.1126/scitranslmed.3002842
|
[13]
|
Guedan, S., Posey, A., Shaw, C., et al. (2018) Enhancing CAR T Cell Persistence through ICOS and 4-1BB Costimulation. JCI Insight, 3, e96976. https://doi.org/10.1172/jci.insight.96976
|
[14]
|
Guedan, S., Madar, A., Casado-Medrano, V., et al. (2020) Single Residue in CD28-Costimulated CAR T Cells Limits Long-Term Persistence and Antitumor Durability. Journal of Clinical Investigation, 130, 3087-3097. https://doi.org/10.1172/JCI133215
|
[15]
|
Sadelain, M., Brentjens, R. and Rivière, I. (2013) The Basic Principles of Chimeric Antigen Receptor Design. Cancer Discovery, 3, 388-398. https://doi.org/10.1158/2159-8290.CD-12-0548
|
[16]
|
Roselli, E., Boucher, J., Li, G., et al. (2021) 4-1BB and Optimized CD28 Co-Stimulation Enhances Function of Human Mono-Specific and Bi-Specific Third-Generation CAR T Cells. Journal for ImmunoTherapy of Cancer, 9, e3354. https://doi.org/10.1136/jitc-2021-003354
|
[17]
|
Cappell, K. and Kochenderfer, J. (2021) A Comparison of Chimeric Antigen Receptors Containing CD28 versus 4-1BB Costimulatory Domains. Nature Reviews Clinical Oncology, 18, 715-727. https://doi.org/10.1038/s41571-021-00530-z
|
[18]
|
Wang, Y., Zhong, K., Ke, J., et al. (2021) Combined 4-1BB and ICOS Co-Stimulation Improves Anti-Tumor Efficacy and Persistence of Dual Anti-CD19/CD20 Chimeric Antigen Receptor T Cells. Cytotherapy, 23, 715-723. https://doi.org/10.1016/j.jcyt.2021.02.117
|
[19]
|
Alizadeh, D., Wong, R.A., Yang, X., et al. (2019) IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype. Cancer Immunology Research, 7, 759-772. https://doi.org/10.1158/2326-6066.CIR-18-0466
|
[20]
|
Alvarez Fernandez, C., Escribà Garcia, L., Caballero, A., et al. (2021) Memory Stem T Cells Modified with a Redesigned CD30-Chimeric Antigen Receptor Show an Enhanced Antitumor Effect in Hodgkin Lymphoma. Clinical & Translational Immunology, 10, e1268. https://doi.org/10.1002/cti2.1268
|
[21]
|
Hurton, L., Singh, H., Najjar, A., et al. (2016) Tethered IL-15 Augments Antitumor Activity and Promotes a Stem-Cell Memory Subset in Tumor-Specific T Cells. Proceedings of the National Academy of Sciences of the United States of America, 113, e7788-e7797. https://doi.org/10.1073/pnas.1610544113
|
[22]
|
Aspuria, P., Vivona, S., Bauer, M., et al. (2021) An Orthogonal IL-2 and IL-2Rβ System Drives Persistence and Activation of CAR T Cells and Clearance of Bulky Lymphoma. Science Translational Medicine, 13, g7565. https://doi.org/10.1126/scitranslmed.abg7565
|
[23]
|
Agliardi, G., Liuzzi, A., Hotblack, A., et al. (2021) Intratumoral IL-12 Delivery Empowers CAR-T Cell Immunotherapy in a Pre-Clinical Model of Glioblastoma. Nature Communications, 12, Article No. 444. https://doi.org/10.1038/s41467-020-20599-x
|
[24]
|
Kosaka, H., Yoshimoto, T., Yoshimoto, T., et al. (2008) Interferon—Is a Therapeutic Target Molecule for Prevention of Postoperative Adhesion Formation. Nature medicine, 14, 437-441. https://doi.org/10.1038/nm1733
|
[25]
|
Raué, H., Beadling, C., Haun, J., et al. (2013) Cytokine-Mediated Programmed Proliferation of Virus-Specific CD8+ Memory T Cells. Immunity, 38, 131-139. https://doi.org/10.1016/j.immuni.2012.09.019
|
[26]
|
Pang, N., Shi, J., Qin, L., et al. (2021) IL-7 and CCL19-Secreting CAR-T Cell Therapy for Tumors with Positive Glypican-3 or Mesothelin. Journal of Hematology & Oncology, 14, Article No. 118. https://doi.org/10.1186/s13045-021-01128-9
|
[27]
|
Philipson, B.I., O’Connor, R., May, M.C., et al. (2020) 4-1BB Costimulation Promotes CAR T Cell Survival through Noncanonical NF-κB Signaling. Science Signaling, 13, y8248. https://doi.org/10.1126/scisignal.aay8248
|
[28]
|
Zhang, X., Lv, X. and Song, Y. (2017) Short-Term Culture with IL-2 Is Beneficial for Potent Memory Chimeric Antigen Receptor T Cell Production. Biochemical and Biophysical Research Communications, 495, 1833-1838. https://doi.org/10.1016/j.bbrc.2017.12.041
|
[29]
|
Singh, A. and McGuirk, J. (2020) CAR T Cells: Continuation in a Revolution of Immunotherapy. The Lancet Oncology, 21, e168-e178. https://doi.org/10.1016/S1470-2045(19)30823-X
|
[30]
|
Ti, D., Niu, Y., Wu, Z., et al. (2018) Genetic Engineering of T Cells with Chimeric Antigen Receptors for Hematological Malignancy Immunotherapy. Science China Life Sciences, 61, 1320-1332. https://doi.org/10.1007/s11427-018-9411-4
|
[31]
|
Li, Y.H. and Wang, J.X. (2019) Research Progress of CAR-T Cell Therapy for Multiple Myelom. Modern Oncology Medicine, 27, 3729-3732.
|
[32]
|
Schmidts, A., Wehrli, M. and Maus, M. (2021) Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity. Annual Review of Medicine, 72, 365-382. https://doi.org/10.1146/annurev-med-061119-015600
|
[33]
|
Morgan, R., Yang, J., Kitano, M., et al. (2010) Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2. Molecular Therapy: The Journal of the American Society of Gene Therapy, 18, 843-851. https://doi.org/10.1038/mt.2010.24
|
[34]
|
Liu, G., Rui, W., Zhao, X., et al. (2021) Enhancing CAR-T Cell Efficacy in Solid Tumors by Targeting the Tumor Microenvironment. Cellular & Molecular Immunology, 18, 1085-1095. https://doi.org/10.1038/s41423-021-00655-2
|
[35]
|
Hou, A., Chen, L. and Chen, Y. (2021) Navigating CAR-T Cells through the Solid-Tumour Microenvironment. Nature Reviews Drug Discovery, 20, 531-550. https://doi.org/10.1038/s41573-021-00189-2
|
[36]
|
Wang, Y., Luo, F., Yang, J., et al. (2017) New Chimeric Antigen Receptor Design for Solid Tumors. Frontiers in Immunology, 8, Article 1934. https://doi.org/10.3389/fimmu.2017.01934
|
[37]
|
Lv, B., Wang, Y., Ma, D., et al. (2022) Immunotherapy: Reshape the Tumor Immune Microenvironment. Frontiers in Immunology, 13, Article 844142. https://doi.org/10.3389/fimmu.2022.844142
|
[38]
|
Li, G. and Wong, A. (2008) EGF Receptor Variant III as a Target Antigen for Tumor Immunotherapy. Expert Review of Vaccines, 7, 977-985. https://doi.org/10.3389/fimmu.2022.844142
|
[39]
|
Rourke, D., Nasrallah, M., Morrissette, J., et al. (2016) Abstract LB-083: Phase I Study of T Cells Redirected to EGFRvIII with a Chimeric Antigen Receptor in Patients with EGFRvIII+ Glioblastoma. Cancer Research, 76, LB-083. https://doi.org/10.1158/1538-7445.AM2016-LB-083
|
[40]
|
Park, A., Fong, Y., Kim, S., et al. (2020) Effective Combination Immunotherapy Using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors. Science Translational Medicine, 12, eaaz1863. https://doi.org/10.1126/scitranslmed.aaz1863
|
[41]
|
Hernandez-Lopez, R.A., Yu, W., Cabral, K.A., et al. (2021) T Cell Circuits that Sense Antigen Density with an Ultrasensitive Threshold. Science, 371, 1166-1171. https://doi.org/10.1126/science.abc1855
|
[42]
|
Anurathapan, U., Chan, R., Hindi, H., et al. (2013) Kinetics of Tumor Destruction by Chimeric Antigen Receptor-Modified T Cells. Molecular Therapy. The Journal of the American Society of Gene Therapy, 22, 623-633. https://doi.org/10.1038/mt.2013.262
|
[43]
|
Feng, K., Liu, Y., Guo, Y., et al. (2018) Phase I Study of Chimeric Antigen Receptor Modified T Cells in Treating HER2-Positive Advanced Biliary Tract Cancers and Pancreatic Cancers. Protein & Cell, 9, 838-847. https://doi.org/10.1007/s13238-017-0440-4
|
[44]
|
Murty, S., Haile, S.T., Beinat, C., et al. (2020) Intravital Imaging Reveals Synergistic Effect of CAR T-Cells and Radiation Therapy in a Preclinical Immunocompetent Glioblastoma Model. Oncoimmunology, 9, Article 1757360. https://doi.org/10.1080/2162402X.2020.1757360
|
[45]
|
Zhu, L., Liu, J., Zhou, G., et al. (2021) Remodeling of Tumor Microenvironment by Tumor-Targeting Nanozymes Enhances Immune Activation of CAR T Cells for Combination Therapy. Small, 17, Article 2102624. https://doi.org/10.1002/smll.202102624
|
[46]
|
Bocca, P., Carlo, E., Caruana, I., et al. (2017) Bevacizumab-Mediated Tumor Vasculature Remodelling Improves Tumor Infiltration and Antitumor Efficacy of GD2-CAR T Cells in a Human Neuroblastoma Preclinical Model. OncoImmunology, 7, e1378843. https://doi.org/10.1080/2162402X.2017.1378843
|
[47]
|
Caruana, I., Savoldo, B., Hoyos, V., et al. (2015) Heparanase Promotes Tumor Infiltration and Antitumor Activity of CAR-Redirected T Lymphocytes. Nature Medicine, 21, 524-529. https://doi.org/10.1038/nm.3833
|
[48]
|
Lo, A., Wang, L., Scholler, J., et al. (2015) Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. Cancer Research, 75, 2800-2810. https://doi.org/10.1158/0008-5472.CAN-14-3041
|
[49]
|
Watanabe, K., Luo, Y., Da, T., et al. (2018) Pancreatic Cancer Therapy with Combined Mesothelin-Redirected Chimeric Antigen Receptor T Cells and Cytokine-Armed Oncolytic Adenoviruses. JCI Insight, 3, e99573. https://doi.org/10.1172/jci.insight.99573
|
[50]
|
Johnson, L.R., Lee, D.Y., Eacret, J.S., et al. (2021) The Immunostimulatory RNA RN7SL1 Enables CAR-T Cells to Enhance Autonomous and Endogenous Immune Function. Cell, 184, 4981-4995. https://doi.org/10.1016/j.cell.2021.08.004
|
[51]
|
Adusumilli, P., Zauderer, M., Riviere, I., et al. (2021) A Phase I Trial of Regional Mesothelin-Targeted CAR T-Cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. Cancer Discovery, 11, 2748-2763. https://doi.org/10.1158/2159-8290.CD-21-0407
|
[52]
|
Tanoue, K., Rosewell Shaw, A., Watanabe, N., et al. (2017) Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Research, 77, 2040-2051. https://doi.org/10.1158/0008-5472.CAN-16-1577
|
[53]
|
Zou, F., Lu, L., Liu, J., et al. (2019) Engineered Triple Inhibitory Receptor Resistance Improves Anti-Tumor CAR-T Cell Performance via CD56. Nature Communications, 10, Article No. 4109. https://doi.org/10.1038/s41467-019-11893-4
|
[54]
|
Shi, X., Zhang, D., Zhang, Z., et al. (2019) Targeting Glycosylation of PD-1 to Enhance CAR-T Cell Cytotoxicity. Journal of Hematology & Oncology, 12, Article No. 127. https://doi.org/10.1186/s13045-019-0831-5
|
[55]
|
Pan, Z., Di, S., Shi, B., et al. (2018) Increased Antitumor Activities of Glypican-3-Specific Chimeric Antigen Receptor-Modified T Cells by Coexpression of a Soluble PD1-CH3 Fusion Protein. Cancer Immunology, Immunotherapy, 67, 1621-1634. https://doi.org/10.1007/s00262-018-2221-1
|